The Bochum Optimizing Clopidogrel-Aspirin Therapy and MORTality Study (BOCLA-Mort)
Comparing standard treatment versus optimized antiplatelet therapy and outcomes measures.
Coronary Artery Disease
|Study Design:||Observational Model: Case Control
Time Perspective: Retrospective
|Official Title:||Optimized Antiplatelet Therapy With Aspirin and Clopidogrel Improves Mortality Compared to Standard Treatment.|
- Adverse cardiac events (MACE: mortality,rehospitalisation,myocardial infarction) [ Time Frame: Follow up for up to 12 months (retrospective analysis) ] [ Designated as safety issue: No ]MACE-rate
|Study Start Date:||January 2009|
|Study Completion Date:||February 2013|
|Primary Completion Date:||February 2013 (Final data collection date for primary outcome measure)|
Antiplatelet therapy following coronary stenting without platelet function testing
Optimized antiplatelet therapy
Platelet function testing and according to a test and treat strategy improve the antiplatelet therapy in low-responder.
Treatment adjustments were done as published before - see BOCLA-Plan manuscript. (Reference: Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance--the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy. BMC Med. 2011 Jan 12;9:3.)
The study is aimed to evaluate if optimized antiplatelet treatment using a test and treat algorithm (with whole blood aggregometry) is able to improve clinical outcome of patients compared to standard treatment without platelet function testing.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01796691
|Cardiovascular Center, Ruhr-University Bochum|
|Bochum, NRW, Germany, D-44791|
|Principal Investigator:||Horst Neubauer, MD||Ruhr-University Bochum, Cardiovascular Center|